Halozyme Therapeutics Inc (HALO)

[jamtomorrow2]

Could someone please explain to me in plain English why the PRIMAL trial was abandoned

"After assessing recruitment and the enrollment of increasingly later line patients, Halozyme has decided to discontinue the PRIMAL study of PEGPH20 with docetaxel in non-small cell lung cancer patients and focus on immuno-oncology therapy in its ongoing phase 1b study of PEGPH20 in combination with KEYTRUDA®."

A few analysts asked the question at the CC but the replies seemed wishy-washy.

Also at the CC there was a mention of the changed Keytruda trial protocol, which suggested that patients had been given LMW Heparin in order to prevent clots but this had caused bleeding prone patients to bleed. The trial had been halted and now patients will receive a lower dose of LMW Heparin. Does it really make sense to give any patients prone to bleeding LMW Heparin? Could there be a chance that this Keytruda trial could be halted again if the bleeding continues - shades of Cinryse?